Login to Your Account



FDA Panel Vote on CAP Studies Could Affect Pending NDAs

By Donna Young


Thursday, March 27, 2008
The FDA is re-evaluating the appropriateness of using noninferiority trial designs for anti-infectives used to treat community-acquired pneumonia (CAP), which could affect firms like Woodridge, Ill.-based Advanced Life Sciences Holdings Inc., whose new drug applications are in the works. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription